相关实验视频

Updated: Jul 10, 2025

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

抗脂抗体在急性COVID-19后得到丰富,但不会调节血栓风险

Marc Emmenegger¹, Vishalini Emmenegger², Srikanth Mairpady Shambat³

¹Institute of Neuropathology, University of Zurich, 8091 Zurich, Switzerland; Division of Medical Immunology, Department of Laboratory Medicine, University Hospital Basel, 4031 Basel, Switzerland.

Clinical immunology (Orlando, Fla.)

|November 23, 2023

概括

抗脂抗体 (aPL) 像IgM对抗附件V,β2糖蛋白I和前热血素,以及IgG对抗心脏素,在COVID-19患者中是升高的. 然而,这些抗体与COVID-19中血栓形成的风险增加无关.

科学领域:

免疫学免疫学免疫学
病毒学病毒学
血液学血液学血液学

背景情况:

与COVID-19相关的凝血病与抗脂综合征 (APS) 有共同特征.
在COVID-19患者中报告了抗脂抗体 (aPL) 的升高,但它们与临床事件的关联尚不清楚.
COVID-19在分子特征中表现出异质性,包括自身抗体和细胞因子概况.

研究的目的:

在COVID-19患者中表征抗脂抗体,抗SARS-CoV-2抗体和细胞因子概况.
将这些个人资料与接种疫苗的个人和流感患者进行比较.
评估aPL存在与COVID-19中血栓事件之间的关联.

主要方法:

使用微ELISA和线性免疫试验 (LIA) 对10种抗原进行抗SARS-CoV-2IgG/IgA和抗脂抗体 (aPL) 的分析.
在血样本中测量了16种细胞因子和化学因子.
多变量回归分析包括临床和人口参数.

主要成果:

在COVID-19患者中观察到对附件V (AnV),β2-糖蛋白I (β2GPI) 和前列血栓 (PT) 的IgM自身抗体升高.
与对照组相比,COVID-19患者的抗脂抗体水平 (PT,β2GPI,AnV IgM;CL IgG) 在COVID-19患者中显著更高.
这些aPL水平与抗SARS-CoV-2抗体标位相关,而COVID-19疾病严重程度是血栓形成的主要相关值.

结论:

重新总结了之前关于COVID-19中aPL升高的研究结果.
在COVID-19中存在特定的aPL (PT,β2GPI,AnV IgM,CL IgG) 与血栓事件的发生率增加无关.

关键词:

抗脂抗体是一种抗脂抗体.这是一种自身免疫力.贝叶斯分析是贝叶斯分析.细胞因子 (cytokines) 是一种细胞因子.流行病学流行病学流感是一次流感.这是天生的免疫力.随机森林回归随机森林回归这就是SARS-CoV-2病毒.病毒学病毒学

更多相关视频

Ferric Chloride-induced Murine Thrombosis Models

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

相关概念视频

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Disorders of Hemostasis

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.